RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
30
10
2020
accepted:
26
07
2021
revised:
14
07
2021
pubmed:
11
8
2021
medline:
27
1
2022
entrez:
10
8
2021
Statut:
ppublish
Résumé
The activity of Rho family GTPase protein, RAC1, which plays important normal physiological functions, is dysregulated in multiple cancers. RAC1 is expressed in both estrogen receptor alpha (ER)-positive and ER-negative breast cancer (BC) cells. However, ER-positive BC is more sensitive to RAC1 inhibition. We have determined that reducing RAC1 activity, using siRNA or EHT 1864 (a small molecule Rac inhibitor), leads to rapid ER protein degradation. RAC1 interacts with ER within the ER complex and RAC1 localizes to chromatin binding sites for ER upon estrogen treatment. RAC1 activity is important for RNA Pol II function at both promoters and enhancers of ER target genes and ER-regulated gene transcription is blocked by EHT 1864, in a dose-dependent manner. Having identified that RAC1 is an essential ER cofactor for ER protein stability and ER transcriptional activity, we report that RAC1 inhibition could be an effective therapeutic approach for ER-positive BC.
Identifiants
pubmed: 34373577
doi: 10.1038/s41388-021-01985-1
pii: 10.1038/s41388-021-01985-1
pmc: PMC8497275
doi:
Substances chimiques
Estrogen Receptor alpha
0
RAC1 protein, human
0
rac1 GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
5950-5962Subventions
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166835
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225–40.
pubmed: 23043248
doi: 10.1146/annurev-physiol-030212-183708
Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer care in the United States. JAMA Oncol. 2017;3:928–35.
pubmed: 28152150
pmcid: 5824237
doi: 10.1001/jamaoncol.2016.6380
Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature. 1975;256:592–3.
pubmed: 170527
doi: 10.1038/256592a0
Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941–51.
pubmed: 3690665
doi: 10.1016/0092-8674(87)90581-2
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor–regulated transcription. Cell. 2000;103:843–52.
pubmed: 11136970
doi: 10.1016/S0092-8674(00)00188-4
Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, et al. Coactivator function defines the active estrogen receptor alpha cistrome. Mol Cell Biol. 2009;29:3413–23.
pubmed: 19364822
pmcid: 2698732
doi: 10.1128/MCB.00020-09
Johnson AB, O’Malley BW. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol. 2012;348:430–9.
pubmed: 21664237
doi: 10.1016/j.mce.2011.04.021
Yi P, Wang Z, Feng Q, Chou CK, Pintilie GD, Shen H. et al. Structural and functional impacts of ER coactivator sequential recruitment. Mol Cell. 2017;67:733–43.
pubmed: 28844863
pmcid: 5657569
doi: 10.1016/j.molcel.2017.07.026
Narumiya S, Thumkeo D. Rho signaling research: history, current status and future directions. FEBS Lett. 2018;592:1763–76.
pubmed: 29749605
pmcid: 6032899
doi: 10.1002/1873-3468.13087
Hajdo-Milašinović A, Ellenbroek SIJ, van Es S, van der Vaart B, Collard JG. Rac1 and Rac3 have opposing functions in cell adhesion and differentiation of neuronal cells. J Cell Sci. 2007;120:555–66.
pubmed: 17244648
doi: 10.1242/jcs.03364
Payapilly A, Malliri A. Compartmentalisation of RAC1 signalling. Curr Opin Cell Biol. 2018;54:50–6.
pubmed: 29723737
doi: 10.1016/j.ceb.2018.04.009
Kazanietz MG, Caloca MJ. The Rac GTPase in cancer: from old concepts to new paradigms. Cancer Res. 2017;77:5445–51.
pubmed: 28807941
pmcid: 5645227
doi: 10.1158/0008-5472.CAN-17-1456
Maldonado MDM, Dharmawardhane S. Targeting Rac and Cdc42 GTPases in cancer. Cancer Res. 2018;78:3101–11.
pubmed: 29858187
doi: 10.1158/0008-5472.CAN-18-0619
Nagase M, Fujita T. Role of Rac1–mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9:86.
pubmed: 23296296
doi: 10.1038/nrneph.2012.282
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251–63.
pubmed: 22817889
pmcid: 3600117
doi: 10.1016/j.cell.2012.06.024
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006–14.
pubmed: 22842228
pmcid: 3432702
doi: 10.1038/ng.2359
Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000;19:3013–20.
pubmed: 10871853
doi: 10.1038/sj.onc.1203621
Yang C, Liu Y, Lemmon MA, Kazanietz MG. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol Cell Biol. 2006;26:831–42.
pubmed: 16428439
pmcid: 1347034
doi: 10.1128/MCB.26.3.831-842.2006
Goka ET, Lippman ME. Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene. 2015;34:5395–405.
pubmed: 25659579
pmcid: 4633721
doi: 10.1038/onc.2014.468
Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase–specific small molecule inhibitor. Methods in Enzymology. Vol. 406. New York: Academic Press; 2006. p. 554–65.
Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007;282:35666–78.
pubmed: 17932039
doi: 10.1074/jbc.M703571200
Goka ET, Chaturvedi P, Lopez DTM, Garza ADL, Lippman ME. RAC1b overexpression confers resistance to chemotherapy treatment in colorectal cancer. Mol Cancer Therapeutics. 2019;18:957–68.
doi: 10.1158/1535-7163.MCT-18-0955
Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods in Enzymology, Vol. 439. New York: Academic Press; 2008. p. 111–29.
Reinbolt RE, Mangini N, Hill JL, Levine LB, Dempsey JL, Singaravelu J, et al. Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. Semin Oncol Nurs. 2015;31:146–55.
pubmed: 25951743
doi: 10.1016/j.soncn.2015.02.002
Szostakowska M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173:489–97.
pubmed: 30382472
doi: 10.1007/s10549-018-5023-4
AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol (Tor, Ont). 2018;25:S18–27.
doi: 10.3747/co.25.3752
Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166:41–54.
pubmed: 28741274
doi: 10.1007/s10549-017-4385-3
Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Desire L, et al. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer. 2011;18:207–19.
pubmed: 21118977
pmcid: 3644524
Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, et al. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget. 2017;8:21806–17.
pubmed: 28423521
pmcid: 5400625
doi: 10.18632/oncotarget.15586
Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke CA, et al. RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene. 2016;35:6319–29.
pubmed: 27181206
pmcid: 5112160
doi: 10.1038/onc.2016.163
Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993;53:3229–32.
pubmed: 8324732
Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003;144:4562–74.
pubmed: 12959972
doi: 10.1210/en.2003-0567
Nawaz Z, Lonard DM, Dennis AP, Smith CL, O’Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci U.S.A. 1999;96:1858–62.
pubmed: 10051559
pmcid: 26701
doi: 10.1073/pnas.96.5.1858
Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Investig. 2007;117:2205–15.
pubmed: 17627304
pmcid: 1906730
doi: 10.1172/JCI21739
Nonclercq D, Journé F, Body JJ, Leclercq G, Laurent G. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Mol Cell Endocrinol. 2004;227:53–65.
pubmed: 15501584
doi: 10.1016/j.mce.2004.07.003
Paulsen MT, Veloso A, Prasad J, Bedi K, Ljungman EA, Tsan YC, et al. Coordinated regulation of synthesis and stability of RNA during the acute TNF-induced proinflammatory response. Proc Natl Acad Sci U.S.A. 2013;110:2240–5.
pubmed: 23345452
pmcid: 3568384
doi: 10.1073/pnas.1219192110
Korkmaz G, Lopes R, Ugalde AP, Nevedomskaya E, Han R, Myacheva K, et al. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol. 2016;34:192–8.
pubmed: 26751173
doi: 10.1038/nbt.3450
Bates M, Huang B, Dempsey GT, Zhuang X. Multicolor super-resolution imaging with photo-switchable fluorescent probes. Science. 2007;317:1749–53.
pubmed: 17702910
pmcid: 2633025
doi: 10.1126/science.1146598
Sugihara K, Nakatsuji N, Nakamura K, Nakao K, Hashimoto R, Otani H, et al. Rac1 is required for the formation of three germ layers during gastrulation. Oncogene. 1998;17:3427–33.
pubmed: 10030666
doi: 10.1038/sj.onc.1202595
Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515–26.
pubmed: 26627737
doi: 10.1016/j.cell.2015.11.015
Lanning CC, Daddona JL, Ruiz-Velasco R, Shafer SH, Williams CL. The Rac1 C-terminal polybasic region regulates the nuclear localization and protein degradation of Rac1. J Biol Chem. 2004;279:44197–210.
pubmed: 15304504
doi: 10.1074/jbc.M404977200
Navarro-Lérida I, Pellinen T, Sanchez SA, Guadamillas MC, Wang Y, Mirtti T, et al. Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion. Developmental Cell. 2015;32:318–34.
pubmed: 25640224
doi: 10.1016/j.devcel.2014.12.019
Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, et al. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001;61:5771–7.
pubmed: 11479214
Buongiorno P, Pethe VV, Charames GS, Esufali S, Bapat B. Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells. Mol Cancer. 2008;7:73.
pubmed: 18826597
pmcid: 2565678
doi: 10.1186/1476-4598-7-73
Jamieson C, Lui C, Brocardo MG, Martino-Echarri E, Henderson BR. Rac1 augments Wnt signaling by stimulating beta-catenin-lymphoid enhancer factor-1 complex assembly independent of beta-catenin nuclear import. J Cell Sci. 2015;128:3933–46.
pubmed: 26403202
pmcid: 4657330
Kurdi AT, Bassil R, Olah M, Wu C, Xiao S, Taga M, et al. Tiam1/Rac1 complex controls Il17a transcription and autoimmunity. Nat Commun. 2016;7:13048–13048.
pubmed: 27725632
pmcid: 5062600
doi: 10.1038/ncomms13048
Walker MP, Zhang M, Le TP, Wu P, Laine M, Greene GL. RAC3 is a pro-migratory co-activator of ERalpha. Oncogene. 2011;30:1984–94.
pubmed: 21217774
pmcid: 3084334
doi: 10.1038/onc.2010.583
Stewart GS, Wang B, Bignell CR, Taylor AMR, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6.
pubmed: 12607005
doi: 10.1038/nature01446
Liu F, Xu Y, Lu X, Hamard P-J, Karl DL, Man N, et al. PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. Nucleic Acids Res. 2020;48:2956–68.
pubmed: 32025719
pmcid: 7102951
doi: 10.1093/nar/gkaa065
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
pubmed: 22388286
pmcid: 3322381
doi: 10.1038/nmeth.1923
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576–89.
pubmed: 20513432
pmcid: 2898526
doi: 10.1016/j.molcel.2010.05.004
Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160–5.
pubmed: 27079975
pmcid: 4987876
doi: 10.1093/nar/gkw257
Shen L, Shao N, Liu X, Nestler E. ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics. 2014;15:284.
pubmed: 24735413
pmcid: 4028082
doi: 10.1186/1471-2164-15-284
Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105–11.
pubmed: 19289445
pmcid: 2672628
doi: 10.1093/bioinformatics/btp120
Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417–9.
pubmed: 28263959
pmcid: 5600148
doi: 10.1038/nmeth.4197
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013;30:923–30.
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U.S.A. 2005;102:15545–50.
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinforma (Oxf, Engl). 2010;26:139–40.
doi: 10.1093/bioinformatics/btp616
Beckedorff F, Blumenthal E, daSilva LF, Aoi Y, Cingaram PR, Yue J, et al. The human integrator complex facilitates transcriptional elongation by endonucleolytic cleavage of nascent transcripts. Cell Rep. 2020;32:107917.
pubmed: 32697989
pmcid: 7427568
doi: 10.1016/j.celrep.2020.107917
Levet F, Julien G, Galland R, Butler C, Beghin A, Chazeau A, et al. A tessellation-based colocalization analysis approach for single-molecule localization microscopy. Nat Commun. 2019;10:2379.
pubmed: 31147535
pmcid: 6542817
doi: 10.1038/s41467-019-10007-4